HOME > BLOG
On October 7th, 2022 the U.S. Food and Drug Administration (FDA) announced its approval of the Boostrix vaccine, commonly known as Tdap (combination of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis) for immunization administration during the third trimester of pregnancy to prevent pertussis in infants younger than two months of age.
Innovation drives progress. When it comes to innovation in the development of new drugs and therapeutic biological products in the pharmaceutical industry, the United States Food and Drug Administration’s (FDA’s) Center for Drug Evaluation and Research (CDER) is a key supporter of the pharmaceutical industry.
On August 9th, 2022, the U.S. Food and Drug Administration issued an emergency use authorization for the JYNNEOS vaccine for Monkeypox. In this blog we dive more into what that means for pharmacists and what they need to make sure their patients know.
On July 6th, 2022 the FDA revised the Emergency Use Authorization (EUA) for Paxlovid. With this update, licensed pharmacists were granted the ability to prescribe Paxlovid to eligible patients, with certain limitations existing to ensure the safety and correct use of the medication. In today’s blog post, we will discuss this approval and what pharmacies need to know.
This free online course offered by UT Austin helps healthcare professionals combat opioid-related overdose and addiction disorder.
Since 1980, the number of deaths from drug overdose has increased by 500%. In 2009, deaths from drug overdoses outnumbered car accident fatalities. As the epidemic of prescription drugs and illicit opioid overdoses continues to grow, access to naloxone is being...
Your monthly email to stay up to date with the latest in healthcare and technology.
Get Started With Your Demo Today.
Existing customer looking for help? Head to our contact us page and fill out the form, or give us a call: 877-959-7550